

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA Enzalutamide for metastatic hormone-relapsed prostate cancer previously treated with a docetaxel-containing regimen

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Consultation

1. Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how?

The potential for a subpopulation comprised of transgendered people was raised during the scoping workshop. NICE clarified that this population is included in the overall population of adults with metastatic hormone-relapsed prostate cancer who have previously received treatment with a docetaxel-containing chemotherapy regimen.

2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the Committee addressed these?

Yes; patient experts considered it important to ensure that access to enzalutamide is equitable, and that patients are not denied treatment because of their age, ethnicity or socioeconomic background. Because the Committee does not make recommendations based on these factors, this was not considered a relevant equality issue.

3. Have any other potential equality issues been identified by the Committee, and, if so, how has the Committee addressed these?

No potential equality issues have been identified by the Committee.

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

It is not expected that the preliminary recommendations will make it more difficult in practice for a specific group to access the technology compared with other groups.

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No.

6. Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

Not applicable.

7. Have the Committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?

There were no specific Committee considerations of equality issues because the potential equality issues identified were not considered relevant. The issues raised during the scoping process and in the expert statements were summarised in the first appraisal consultation document's summary table.

Approved by Associate Director (name): Elisabeth George

Date: 10/10/13

Second consultation

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the Committee addressed these?

No additional potential equality issues were raised during consultation.

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

The recommendations have changed after consultation. They were widened to include treatment for people who have received more than 1 chemotherapy. It was also specified that enzalutamide was not recommended for people who have had treatment with abiraterone because of lack of evidence in this group.

3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No.

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

No.

5. Have the Committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

There were no specific Committee considerations on equality issues because the potential equality issues identified were not considered relevant. The issues raised during the scoping process and in the expert statements were summarised in the second appraisal consultation document's summary table.

Approved by Associate Director (name): Elisabeth George

Date: 21/01/14

Final appraisal determination

(when an ACD issued)

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the Committee addressed these?

No additional potential equality issues were raised during consultation.

2. If the recommendations have changed after the second consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

The recommendations have changed after consultation. Treatment of people who have had previous treatment with abiraterone is no longer included in the guidance.

3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of

the disability?
No.

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?
No.

5. Have the Committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?
There were no specific Committee considerations of equality issues because the potential equality issues identified were not considered relevant. The issues raised during the scoping process and in the expert statements were summarised in the final appraisal determination's summary table.

Approved by Centre or Programme Director (name): Meindert Boysen

Date: 21/07/14